Omeros (OMER) Gross Margin (2014 - 2026)

Omeros (OMER) reported Gross Margin of 94.07% for Q1 2026, down 31.42% sequentially from 137.17% in Q4 2021.

Omeros (OMER) Gross Margin (2014 - 2026) Analysis & Trends

Omeros (OMER) has 9 years of Gross Margin data on file, last reported at 94.07% in Q1 2026.

For the quarter ending Q1 2026, Gross Margin changed N/A year-over-year to 94.07%; the trailing twelve-month figure through Mar 2026 stood at 261.58% (down 34349.0% YoY), and the FY2020 full-year result was 98.78%, down 45.0% from the prior year.
Gross Margin retreated to 94.07% in Q1 2026, from 137.17% in the prior quarter.
In the past five years, Gross Margin ranged from a high of 94.07% in Q1 2026 to a low of 94.07% in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	88.95%
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	86.85%
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	91.79%
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	90.68%
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Omeros	707.67 Mn	707.67 Mn	9.31 Mn	94.07%

Historic Data

Download Data

Date	Value
Mar 31, 2026	94.07%
Dec 31, 2021	137.17%
Sep 30, 2021	98.89%
Jun 30, 2021	98.81%
Mar 31, 2021	98.75%
Dec 31, 2020	99.18%
Sep 30, 2020	98.46%
Jun 30, 2020	98.91%
Mar 31, 2020	98.87%
Dec 31, 2019	98.80%
Sep 30, 2019	99.07%
Jun 30, 2019	99.79%
Mar 31, 2019	99.40%
Dec 31, 2018	99.29%
Sep 30, 2018	99.22%
Jun 30, 2018	92.99%
Mar 31, 2018	87.22%
Dec 31, 2017	96.62%
Sep 30, 2017	99.15%
Jun 30, 2017	99.08%